These events appear to be associated with the increased expression of TGF-β1, which may explain the paradoxical drug actions since TGF-β has been implicated in playing dual roles as both the tumor suppressor and the tumor promoter in pancreatic cancer development [96]. The gene discussed is TGFB1; the disease is pancreatic neoplasm.